Monographie - Foscarnet sodium - Stabilis 4.0

Poslední aktualizace :
28/04/2024

Priešvirusinis vaistas

Foscarnet sodium

Įpurškimas

Tirpalų stabilumas

Mišinių stabilumas

Stabilumą lemiantys veiksniai

Suderinamumas

Leidimo būdai

Bibliografija

Pdf

Cheminė sandara

Prekinis pavadinimas

Prekinis pavadinimas

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Foscarnet	Argentina, Čilė, Jungtinės Amerikos Valstijos
Foscarvir	Japonija
Foscavir	Australija, Austrija, Belgija, Didžioji Britanija, Graikija, Ispanija, Italija, Jungtinės Amerikos Valstijos, Liuksemburgas, Naujojoje Zelandijoje, Olandija, Prancūzija, Švedija, Šveicarija, Vengrija, Vokietija

Bibliografija

Įpurškimas

Bibliografija : Foscarnet sodium

	Tipas	Leidinys
2	Žurnalas	Woods K, Steinmann W, Bruns L, Neels JT. Stability of foscarnet in 0.9% sodium chloride injection. Am J Hosp Pharm 1994 ; 51: 88-90.
36	Žurnalas	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
64	Žurnalas	DiStefano JE, Outman WR. Additional data on visual compatibility of foscarnet sodium with morphine sulfate. Am J Hosp Pharm 1992 ; 49: 1672.
73	Žurnalas	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
75	Žurnalas	Mathew M, Das Gupta V, Bethea C. Stability of foscarnet sodium in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther 1994 ; 19: 35-36.
132	Žurnalas	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
246	Žurnalas	McDonald C, Boddy M, Garas G. The stability of foscarnet in the presence of potassium. Aust J Hosp Pharm 1996 ; 26: 560-561.
496	Žurnalas	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laboratorija	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
1135	Žurnalas	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
2262	Žurnalas	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3595	Laboratorija	Aciclovir - Summary of Product Characteristics Hospira 2009
3662	Laboratorija	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	Žurnalas	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3883	Laboratorija	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
4319	Žurnalas	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.

Mentions Légales